The Drug that won the Nobel Prize

A Newsletter Feed, Health

Everything in italics, I wrote during the pandemic when every mention criticizing the government’s draconian instructions would send our emails to spam. Nowa days, it is slightly less strict but not by much. However, the success of very cheap, easily available drugs is hard to keep silent and I present the results of Dr. William Makis, below.

The dr*g was recognized in 2015 by the Nobel Committee for Physiology or Medicine. The discovery of iv*rm*ctin was acknowledged for its significant impact in the treatment of several tropical diseases.

The dr*g, developed by Japanese scientist Satoshi Ōmura and Irish-born scientist William C. Campbell, has proven to be highly effective in combating p*rasitic infections such as river blindness (onchocerciasis) and lymphatic filariasis (elephantiasis). These diseases affect millions of people in developing countries, primarily in Africa, Central and South America, and Southeast Asia.

The discovery and development of the dr*g opened up new possibilities for treating and preventing these neglected tropical diseases, leading to significant improvements in public health and the quality of life for affected populations.

It was found to be effective fighting the recent worldwide v*rus in Japan, some African countries and India. But then came the crushing “peer-reviewed” studies. It is being suggested that that B*g Ph*r*a is responsible for the suppression of such a cheaply produced medicine.

Dr. William Makis, a Canadian oncologist and radiologist, has gained attention for his pioneering work with repurposed drugs like ivermectin, fenbendazole, and mebendazole as alternative cancer treatments. His approach challenges conventional oncology by leveraging affordable, off-patent medications, which he argues show promising results, particularly in cases of aggressive “turbo cancers” linked to mRNA vaccines. Makis cites peer-reviewed studies, including a September 2024 protocol he co-authored, demonstrating the synergistic anti-cancer effects of these drugs. Fenbendazole, for instance, has at least 12 proven anti-cancer mechanisms, while ivermectin has shown efficacy in halting tumor progression in some stage 4 patients.

Makis’ success stories, shared on platforms like X, include patients with shrinking tumors and improved outcomes after being abandoned by mainstream healthcare. These low-cost drugs—often veterinary-grade but molecularly identical to human versions—offer accessibility, costing pennies compared to Big Pharma’s exorbitant chemotherapies. Makis argues that the trillion-dollar cancer industry suppresses these treatments to protect profits, as off-patent drugs lack financial incentive for clinical trials. Despite facing professional repercussions, he persists, advocating for patient-centered care over corporate interests.

His work empowers patients, offering hope where conventional treatments fail, and sparks a paradigm shift toward affordable, effective cancer care. By exposing systemic resistance from Big Pharma, Makis champions a future where cancer treatment prioritizes healing over greed.